Compare Stocks: ARDX, KYKOF, SFOSF, KHTRF, ACIU, and BMEA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.76	$2.52	$2.10 ▼ $4.00	$280.89M	1.6	182,136 shs	105,361 shs
ARDX Ardelyx	$3.58	$4.46	$3.56 ▼ $8.40	$892.10M	0.7	3.61 million shs	5.69 million shs
BMEA Biomea Fusion	$1.74	$1.44	$0.87 ▼ $2.99	$126.12M	-0.23	2.22 million shs	1.47 million shs
KHTRF Knight Therapeutics	$7.15	$6.95	$4.07 ▼ $7.40	N/A	N/A	7,902 shs	2,500 shs
KYKOF Kyowa Kirin	$15.80	$14.57	$12.42 ▼ $18.00	N/A	N/A	5,073 shs	35,250 shs
SFOSF Shanghai Fosun Pharmaceutical (Group)	$1.93	$2.16	$1.93 ▼ $3.50	N/A	N/A	1,371 shs	2,958 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	0.00%	-3.50%	+10.84%	+17.95%	+13.58%
ARDX Ardelyx	0.00%	-5.29%	-11.82%	-36.97%	-45.84%
BMEA Biomea Fusion	0.00%	-14.29%	+31.82%	+45.00%	-9.84%
KHTRF Knight Therapeutics	0.00%	-1.24%	+7.26%	+5.77%	+53.60%
KYKOF Kyowa Kirin	0.00%	0.00%	+9.53%	+9.53%	-7.76%
SFOSF Shanghai Fosun Pharmaceutical (Group)	0.00%	-12.18%	-0.92%	-4.36%	-38.67%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.76	$2.52	$2.10 ▼ $4.00	$280.89M	1.6	182,136 shs	105,361 shs
ARDX Ardelyx	$3.58	$4.46	$3.56 ▼ $8.40	$892.10M	0.7	3.61 million shs	5.69 million shs
BMEA Biomea Fusion	$1.74	$1.44	$0.87 ▼ $2.99	$126.12M	-0.23	2.22 million shs	1.47 million shs
KHTRF Knight Therapeutics	$7.15	$6.95	$4.07 ▼ $7.40	N/A	N/A	7,902 shs	2,500 shs
KYKOF Kyowa Kirin	$15.80	$14.57	$12.42 ▼ $18.00	N/A	N/A	5,073 shs	35,250 shs
SFOSF Shanghai Fosun Pharmaceutical (Group)	$1.93	$2.16	$1.93 ▼ $3.50	N/A	N/A	1,371 shs	2,958 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	0.00%	-3.50%	+10.84%	+17.95%	+13.58%
ARDX Ardelyx	0.00%	-5.29%	-11.82%	-36.97%	-45.84%
BMEA Biomea Fusion	0.00%	-14.29%	+31.82%	+45.00%	-9.84%
KHTRF Knight Therapeutics	0.00%	-1.24%	+7.26%	+5.77%	+53.60%
KYKOF Kyowa Kirin	0.00%	0.00%	+9.53%	+9.53%	-7.76%
SFOSF Shanghai Fosun Pharmaceutical (Group)	0.00%	-12.18%	-0.92%	-4.36%	-38.67%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	2.50	Moderate Buy	$7.50	171.74% Upside
ARDX Ardelyx	2.75	Moderate Buy	$13.90	288.27% Upside
BMEA Biomea Fusion	2.67	Moderate Buy	$9.00	417.24% Upside
KHTRF Knight Therapeutics	3.00	Buy	N/A	N/A
KYKOF Kyowa Kirin	1.50	Reduce	N/A	N/A
SFOSF Shanghai Fosun Pharmaceutical (Group)	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ARDX, KYKOF, SFOSF, KHTRF, ACIU, and BMEA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	KYKOF Kyowa Kirin	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold
8/24/2026	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/24/2026	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	ACIU AC Immune	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
8/18/2026	ARDX Ardelyx	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$9.00
8/17/2026	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$16.00 ➝ $15.00
8/10/2026	ARDX Ardelyx	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$14.00 ➝ $11.00
8/7/2026	KHTRF Knight Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/7/2026	ARDX Ardelyx	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$13.00 ➝ $10.00
8/7/2026	ARDX Ardelyx	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
8/7/2026	ARDX Ardelyx	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$17.00 ➝ $14.00

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$4.31M	65.17	N/A	N/A	$0.54 per share	5.11
ARDX Ardelyx	$407.32M	2.19	N/A	N/A	$0.69 per share	5.19
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$0.42 per share	N/A
KHTRF Knight Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
KYKOF Kyowa Kirin	N/A	N/A	N/A	N/A	N/A	N/A
SFOSF Shanghai Fosun Pharmaceutical (Group)	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$85.03M	-$0.54	N/A	16.24	N/A	-245.32%	-100.17%	-28.36%	11/3/2026 (Estimated)
ARDX Ardelyx	-$61.60M	-$0.22	N/A	14.92	N/A	-12.35%	-36.00%	-10.77%	10/29/2026 (Estimated)
BMEA Biomea Fusion	-$61.80M	-$0.29	N/A	N/A	N/A	N/A	-253.73%	-97.91%	11/3/2026 (Estimated)
KHTRF Knight Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	11/5/2026 (Estimated)
KYKOF Kyowa Kirin	N/A	$34.33	0.46	N/A	N/A	N/A	N/A	N/A	10/29/2026 (Estimated)
SFOSF Shanghai Fosun Pharmaceutical (Group)	N/A	$1.17	1.65	N/A	N/A	N/A	N/A	N/A	N/A

Latest ARDX, KYKOF, SFOSF, KHTRF, ACIU, and BMEA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	ACIU AC Immune	-$0.1044	$0.03	+$0.1344	$0.03	$9.59 million	$18.67 million
8/6/2026	Q2 2026	ARDX Ardelyx	-$0.05	-$0.07	-$0.02	-$0.07	$121.04 million	$120.88 million
8/6/2026	Q2 2026	BMEA Biomea Fusion	-$0.2235	-$0.12	+$0.1035	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
KHTRF Knight Therapeutics	N/A	N/A	N/A	N/A	N/A
KYKOF Kyowa Kirin	$19.94	126.20%	N/A	58.08%	N/A
SFOSF Shanghai Fosun Pharmaceutical (Group)	$0.27	13.98%	N/A	23.08%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	0.11	0.93	1.02
ARDX Ardelyx	1.69	3.34	3.15
BMEA Biomea Fusion	N/A	3.47	3.47
KHTRF Knight Therapeutics	N/A	N/A	N/A
KYKOF Kyowa Kirin	N/A	N/A	N/A
SFOSF Shanghai Fosun Pharmaceutical (Group)	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
ARDX Ardelyx	58.92%
BMEA Biomea Fusion	96.72%
KHTRF Knight Therapeutics	24.85%
KYKOF Kyowa Kirin	10.28%
SFOSF Shanghai Fosun Pharmaceutical (Group)	4.64%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
ARDX Ardelyx	5.30%
BMEA Biomea Fusion	10.60%
KHTRF Knight Therapeutics	N/A
KYKOF Kyowa Kirin	N/A
SFOSF Shanghai Fosun Pharmaceutical (Group)	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	101.77 million	97.09 million	Optionable
ARDX Ardelyx	489	249.19 million	235.98 million	Optionable
BMEA Biomea Fusion	50	72.48 million	64.80 million	Optionable
KHTRF Knight Therapeutics	725	N/A	N/A	Not Optionable
KYKOF Kyowa Kirin	5,974	N/A	N/A	Not Optionable
SFOSF Shanghai Fosun Pharmaceutical (Group)	40,370	N/A	N/A	Not Optionable

ARDX, KYKOF, SFOSF, KHTRF, ACIU, and BMEA Headlines

Recent News About These Companies

Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion

September 6, 2026 | prnewswire.com

Shanghai Fosun Pharma Executes HK$3.6 Million H-Share Buyback

August 27, 2026 | tipranks.com

Fosun Pharma Sets August Board Meeting to Approve 2026 Interim Results

August 13, 2026 | tipranks.com

Fosun Pharma Subsidiary Wins Approval for New Type 2 Diabetes Combination Drug

August 3, 2026 | tipranks.com

Fosun Pharma Sets Final 2025 Dividend and Withholding Tax Terms for H-Share Investors

June 16, 2026 | tipranks.com

Fosun Pharma Shareholders Back AGM Resolutions and Final Dividend

June 16, 2026 | tipranks.com

Fosun Pharma Files Unaudited First-Quarter 2026 Report in Line With Hong Kong Rules

April 28, 2026 | tipranks.com

Fosun Pharma Sets April Board Meeting to Approve First-Quarter 2026 Results

April 10, 2026 | tipranks.com

Fosun Pharma Sets March 2026 Board Meeting to Approve 2025 Results and Dividend Plan

March 9, 2026 | tipranks.com

Fosun Pharma Calls 2026 EGM to Advance Spin-off and Hong Kong Listing of Fosun Adgenvax

February 4, 2026 | tipranks.com

Shanghai Fosun Pharmaceutical Schedules 2025 Extraordinary General Meeting

November 7, 2025 | tipranks.com

Fangzhou and Fosun Pharma Forge Strategic Alliance to Deliver AI-Powered Psoriasis Management

October 29, 2025 | financialpost.comF

Shanghai Fosun Pharma Releases 2025 Q3 Report

October 28, 2025 | tipranks.com

Fosun Pharma’s Subsidiary Gains Approval for New Drug Luvometinib

May 29, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX, KYKOF, SFOSF, KHTRF, ACIU, and BMEA Company Descriptions

AC Immune NASDAQ:ACIU

$2.76 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.76 0.00 (-0.18%)

As of 09/11/2026 07:52 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Ardelyx NASDAQ:ARDX

$3.58 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.58 0.00 (0.00%)

As of 07:19 AM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Biomea Fusion NASDAQ:BMEA

$1.74 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.73 -0.01 (-0.57%)

As of 07:18 AM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Knight Therapeutics OTCMKTS:KHTRF

$7.15 0.00 (0.00%)

As of 09/11/2026

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

Kyowa Kirin OTCMKTS:KYKOF

$15.80 0.00 (0.00%)

As of 09/11/2026

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; and Romiplate/Nplate, a genetically recombinant protein that produces platelet through the stimulation of thrombopoietin receptors. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, an anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

Shanghai Fosun Pharmaceutical (Group) OTCMKTS:SFOSF

$1.93 0.00 (0.00%)

As of 09/11/2026 09:34 AM Eastern

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, anti-infection, API's and intermediate, metabolism, alimentary system, cardiovascular and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services, and investment management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARDX, KYKOF, SFOSF, KHTRF, ACIU, and BMEA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARDX, KYKOF, SFOSF, KHTRF, ACIU, and BMEA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARDX, KYKOF, SFOSF, KHTRF, ACIU, and BMEA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX, KYKOF, SFOSF, KHTRF, ACIU, and BMEA Company Descriptions

AC Immune NASDAQ:ACIU

Ardelyx NASDAQ:ARDX

Biomea Fusion NASDAQ:BMEA

Knight Therapeutics OTCMKTS:KHTRF

Kyowa Kirin OTCMKTS:KYKOF

Shanghai Fosun Pharmaceutical (Group) OTCMKTS:SFOSF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools